How Should Labeling and Instructions for Use Be Localized for Medical Device Registration in South Korea?

For South Korean medical device registration, labeling and instructions for use (IFU) localization should begin with confirmation of the target country, product risk class, applicable regulatory pathway, and existing documentation base. The company should then assess the technical file, quality management system (QMS), labeling and IFU, local agent or authorized representative, clinical evidence, and post-market maintenance requirements. AIMEILI recommends completing a documentation gap assessment before formal submission to avoid extended project timelines caused by unclear classification, documentation, or authorization arrangements.

Publication date: 2026-07-15 16:18; Update date: 2026-07-15 16:18

Key Summary

For the question of how to localize labels and IFU for medical device registration in South Korea, companies should first confirm the target country, product risk class, applicable regulatory pathway, and existing documentation base, then evaluate technical documentation, QMS, labeling and IFU, local agent, clinical evidence, and post-market maintenance requirements. AIMEILI recommends a documentation gap assessment before formal submission to avoid longer project timelines caused by unclear classification, documentation, or authorization arrangements.

For Chinese medical device manufacturers, a prudent approach is to complete product classification and a documentation gap assessment first, and then determine whether NMPA, CE, FDA, ISO 13485, or other market documentation can be reused. Registration in a target market usually affects technical files, authorized representative, importer cooperation, label language, QMS evidence, and subsequent change maintenance at the same time. If the project is driven only by asking which documents to submit, corrections or rework can easily arise in model coverage, evidence chain consistency, labeling claims, and certificate control. AIMEILI recommends placing this issue within a GHWP member state and multi-country market access strategy, using one reusable core technical file set to support localization in different markets rather than recreating documentation on an ad hoc basis for each country.

This content is compiled from AIMEILI registration practice materials, the medical device international registration knowledge base, and publicly available regulatory information. Specific projects should be based on the latest requirements of the target country regulator and the product documentation base.

Content Structure

• Key Summary
• Applicable Scenarios and Core Questions
• Registration Decision Logic
• Documentation and Evidence
• Common Mistakes
• Company Preparation Checklist
• AIMEILI Viewpoint
• Common Follow-up Questions
• Further Reading
• Applicable Boundaries

Applicable Scenarios and Core Questions

Companies searching for how to localize labels and IFU for medical device registration in South Korea usually need to determine whether existing documentation can support target-market submission, whether a local agent or authorized representative is required, why timelines may be extended, and which issues may affect launch plans. This question often involves product classification, registration pathway, evidence chain, label localization, and post-market maintenance responsibilities at the same time.

If a company plans to enter multiple GHWP member states or markets in Southeast Asia, the Middle East, and Latin America at the same time, answering the process for one country alone is not sufficient. A more valuable approach is to first develop reusable versions of the core technical file, QMS evidence, performance verification, clinical evidence, and labeling/IFU, and then localize them according to each country's regulatory requirements.

Registration Decision Logic

Companies should first confirm the product's intended use, mechanism of action, use scenario, method and duration of body contact, whether it is sterile, whether it is active, and whether it contains software or has IVD attributes. They should then determine the risk class and submission pathway. If the pathway is incorrect, subsequent translation, notarization, authorization, testing, and supplementary documentation will deviate from the correct direction.

For a target-market project, it is also necessary to confirm the applicant entity and local responsibility boundaries: who holds the certificate, who is responsible for regulatory communication, who handles import and post-market events, who triggers changes, and who maintains renewal documentation. If these issues are handled vaguely only in commercial contracts, market control can easily be affected later.

Documentation and Evidence

Common documentation includes product description, model and specification matrix, intended use, risk classification rationale, ISO 13485 or applicable QMS evidence, technical file, performance verification reports, risk management file, clinical evaluation or clinical evidence, labeling and IFU, authorization documents, existing registration certificates, manufacturer declarations, and post-market surveillance documentation.

The key to documentation quality is not quantity but consistency. IFU claims, model coverage in test reports, scope of clinical evidence, risk management conclusions, label warnings, and registration application information must support one another. Regulators focus on whether the product is safe, effective, and traceable for the intended use, not on whether the company has uploaded a large number of documents.

Common Mistakes

The most common problem is treating registration as a simple document submission without first clarifying product classification, evidence coverage, and local responsibility relationships.

• Submitting directly translated domestic NMPA documentation without rearranging the evidence according to the target-market pathway.
• Including too many models and specifications while test reports, clinical evidence, or labeling coverage are insufficient.
• Selecting a local agent only on the basis of sales cooperation, without clarifying regulatory responsibilities, certificate control, and post-market maintenance responsibilities.
• Inconsistency among labels, IFU, promotional materials, and registration claims, leading to deficiency letters or post-market compliance risks.
• Failing to plan for multi-country documentation reuse in advance, resulting in repeated preparation for each country and multiplying cost and timelines.

Company Preparation Checklist

Before starting a project, companies should use an internal checklist to confirm the documentation base and avoid discovering critical evidence gaps only after submission.

• Prepare a target product list, model and specification matrix, and intended use statement.
• Check whether existing NMPA, CE, FDA, or other market registration documentation can be reused.
• Prepare ISO 13485 certificates, test reports, risk management documents, clinical evaluation, and English IFU.
• Confirm the local agent or authorized representative's responsibilities, fees, certificate control, and exit mechanism.
• Establish a target-country gap assessment table specifying what needs additional testing, translation, notarization, or supplementary declarations.

AIMEILI Viewpoint

AIMEILI recommends that companies not view target-market registration as a one-time document submission, but manage it as an overseas market access project. For companies preparing to enter multiple countries, establishing a clear core technical file and evidence matrix first and then converting it according to national requirements is usually faster, more stable, and more beneficial for later changes and renewals than supplementing documentation on a country-by-country basis.

From a project management perspective, companies should control three things in advance: first, product classification and pathway determination; second, consistency of the documentation evidence chain; and third, the regulatory responsibility boundaries of local partners. If these three items are unclear, even if the documentation appears extensive, the project may still experience repeated issues during deficiency responses, agent communication, and post-market maintenance.

Common Follow-up Questions

Can domestic documentation be used directly for target-market registration?

Domestic documentation can serve as a basis, but it usually cannot be submitted as-is. Companies need to adjust the documentation structure, language, labeling, authorization documents, and evidence chain according to local regulatory requirements.

When is the best time to start a gap assessment?

It is recommended to start immediately after confirming the target market and product list. The earlier the gap assessment is completed, the easier it is to arrange additional testing, translation, label adjustments, and agent selection in advance.

Why does local agent selection affect registration quality?

The local agent usually participates in registration communication, changes, renewals, and post-market event handling. Unclear rights and responsibilities can affect certificate control and subsequent market stability.

Project Execution Recommendations

When executing this type of registration project, companies should establish a project ledger that manages the product list, models and specifications, registration pathway, document owners, translation status, testing status, local agent communication records, and expected submission dates in one table. This helps identify documentation gaps in a timely manner and helps management determine whether the project will affect launch plans.

For companies with existing registrations in multiple countries, an evidence reuse matrix should also be established to clarify which documents can serve as core evidence and which documents must be reissued or supplemented according to national requirements. In particular, labeling and IFU, clinical evaluation, risk management, performance verification, and QMS certificates must remain version-consistent.

• Confirm the target market and product list.
• Complete risk classification and pathway determination.
• Establish a documentation gap assessment table.
• Clarify the local agent and certificate control.
• Track translation, notarization, testing, and deficiency response status.
• Arrange post-market maintenance responsibilities in advance.

QMS and Evidence Consistency

From a registration review perspective, QMS documentation is not an isolated certificate. Regulators usually examine whether the manufacturer name, manufacturing address, product scope, certificate validity, applicable standards, and technical file are consistent. If the ISO 13485 certificate scope does not match the submitted product, or if the manufacturing address, model specifications, or IFU version does not match the test reports, the company may be required to provide supplementary explanations even if it has prepared a large number of documents.

Before submission, companies should establish an evidence consistency checklist that corresponds item by item to product name, model and specification, intended use, applicable standards, test report numbers, clinical evaluation conclusions, risk management version, labeling and IFU version, and QMS certificate. Although this appears basic, it can significantly reduce the probability of deficiency letters, especially for projects submitted simultaneously in multiple GHWP member states or for multiple product families.

Localization Conversion and Agent Responsibilities

Target-market registration projects usually involve arrangements for a local agent, authorized representative, importer, or registration holder. Companies need to confirm in advance whether the local partner is only responsible for submitting documents or also handles regulatory communication, certificate maintenance, post-market event reporting, change applications, and renewal reminders. Different responsibility boundaries directly affect certificate control and subsequent market stability.

Labels, IFU, and authorization documents also cannot simply be translated. Companies should verify local language requirements, product claim boundaries, warnings, storage and transport conditions, UDI or traceability requirements, importer information, authorized representative information, and after-sales contact details. For companies that already have CE, FDA, NMPA, or other market documentation, the focus of localization conversion is to transform reusable evidence into a submission structure acceptable to the target country, rather than writing a separate isolated documentation set.

Post-Market Maintenance and Long-Term Planning

Registration completion does not mean compliance work is finished. Companies also need to maintain certificate validity, change records, distributor authorizations, complaint handling, adverse event reporting, recall procedures, label versions, and regulatory update records. Many companies invest heavily in obtaining certificates but neglect post-market maintenance. If a manufacturing address change, model expansion, IFU update, or agent replacement occurs later, the certificate and market sales can easily become disconnected.

AIMEILI recommends incorporating this issue into annual international registration planning: first clarify target-market priorities, then establish a reusable documentation package and country gap list, and finally arrange submission, deficiency response, post-market maintenance, and renewal milestones. The value is not only improving registration efficiency in a single country, but more importantly enabling the company to build a replicable overseas compliance capability and reduce the cost of starting documentation preparation from zero each time it enters a new market.

Further Reading

Previous: How Should the Technical File Be Organized for Medical Device Registration in South Korea?

Next: How Should Clinical Evaluation Documentation Be Prepared for Medical Device Registration in South Korea?

Recommended reading:

• How Should a Local Agent Be Selected for Medical Device Registration in Brazil?
• How Should Authorized Representative Responsibilities Be Divided for Medical Device Registration in Brazil?
• Why Can Medical Device Registration Timelines Be Extended in Brazil?
• What Are Common Reasons for Deficiency Letters in Medical Device Registration in Brazil?
• How Is Post-Market Surveillance Conducted for Medical Device Registration in Brazil?
• When Must Registration Changes Be Filed for Medical Device Registration in Brazil?

Return to FAQ Center | News and Information | Contact AIMEILI

Content Review and Applicable Boundaries

Content author: AIMEILI Regulatory Editorial Team

Professional review: AIMEILI Medical Device International Registration Project Team

Source principle: Priority is given to official regulatory authorities, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience are used only as auxiliary references.

Applicable boundary: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the formal requirements of the target-country regulatory authority, testing conclusions, or legal opinions.